[Current status and prognosis of immune checkpoint inhibitors for esophageal cancer].

Gao, H J; Shang, X B; Yu, Z T

Gao, H J; Shang, X B; Yu, Z T.

Afiliação

Gao HJ; Department of Thoracic Surgery, the Affiliated Hospital of Qingdao University, Qingdao 266003, China.
Shang XB; Department of Esophageal Cancer, Tianjin's Clinical Research Center for Cancer and Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Yu ZT; Department of Esophageal Cancer, Tianjin's Clinical Research Center for Cancer and Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.

Zhonghua Wai Ke Za Zhi ; 57(10): 77-82, 2019 Oct 01.

Article em Zh | MEDLINE | ID: mdl-31510736

Assuntos

Antineoplásicos Imunológicos/uso terapêutico; Neoplasias Esofágicas/tratamento farmacológico; Receptor de Morte Celular Programada 1/antagonistas & inibidores; Neoplasias Esofágicas/imunologia; Humanos; Imunoterapia/métodos; Prognóstico

Palavras-chave

Esophageal neoplasms; Immune checkpoints; Immunotherapy

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: Zh Revista: Zhonghua Wai Ke Za Zhi Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China País de publicação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google